Brief: Entrada Therapeutics, Inc. Q2 EPS USD -0.78
08/08/2023 12:26
Aug 8 (Reuters) - Entrada Therapeutics, Inc. Q2 collaboration revenue USD 18.17 million vs. IBES estimate USD 9.78 million. * Q2 operating expenses USD 34.469 million * Q2 net income USD -25.928 million * Q2 income from operations USD -16.299 million * Q2 EPS USD -0.78
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview